Navigation Links
Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings
Date:3/1/2012

Cambridge, Mass., and Worcester, Mass., March 1, 2012 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and the University of Massachusetts Medical School (UMMS) reported today that the European Patent Office (EPO) has upheld the Tuschl I '726 patent (EP 1309726) in oral opposition proceedings held in Munich, Germany. The requested claims of the '726 patent were upheld without any modification. Opponents included Sanofi-Aventis Deutschland GmbH, Silence Therapeutics AG, and BASF SE.

Inventors on the patent are David P. Bartel, PhD, a Howard Hughes Medical Institute Investigator and professor of biology at the Massachusetts Institute of Technology; Phillip A. Sharp, PhD, Institute Professor at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and a 1993 Nobel Laureate; Thomas Tuschl, PhD, a Howard Hughes Medical Institute Investigator and professor at Rockefeller University; and Phillip D. Zamore, PhD, a Howard Hughes Medical Institute Investigator and the Gretchen Stone Cook Professor of Biomedical Sciences at the University of Massachusetts Medical School, where he co-directs the RNA Therapeutics Institute.

"The Tuschl family of patents defines key discoveries central to the advancement of RNAi therapeutics to patients," said James P. McNamara, PhD, executive director, Office of Technology Management, University of Massachusetts Medical School. "The Tuschl I patent is a critical invention by Professors Tuschl, Zamore, Bartel, and Sharp regarding the RNAi mechanism. We are pleased to see this patent fully upheld in Europe in these opposition proceedings."

"We are very pleased with the outcome of these opposition proceedings which resulted in the claims from the Tuschl I '726 patent being fully upheld. This decision by the EPO affirms our belief in the validity of these claims, and the novelty of the Tuschl I invention, and supports the relevance of Tuschl
'/>"/>

Contact: Mark Shelton
mark.shelton@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
2. UMass Medical School study points to genetic link in apnea of prematurity
3. UMASS Medical Schools human stem cell bank makes available first seven stem cell lines
4. UMass Amherst biologists use GPS to map bats teeth to explore evolutionary adaptations to diet
5. UMass med school professor wins coveted emerging-investigator award
6. UMass Amherst entomologists begin to control winter moth infestation in eastern Massachusetts
7. UMass researcher points to suppression of evidence on radiation effects by 1946 Nobel Laureate
8. UMass Amherst wins major grant to host $7.5 million Northeast Climate Science Center
9. UMass Amherst ecologists among the first to record and study deep-sea fish noises
10. Inspired by gecko feet, UMass Amherst scientists invent super-adhesive material
11. UMass Amherst chemical engineers say mini-cellulose molecule unlocks biofuel chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... Citrus species are among the most important fruit trees in ... thought to be more than 4,000 years. Until now, however, ... orange ( Citrus sinensis ), lemon ( C. limon ), ... A team of researchers from China has published a study ...
... CAMutant presenilin is infamous for its role in the ... strike people as early as their 30s. In their ... productive side: It helps embryonic motor neurons navigate the ... them in on their way to their proper targets. ...
... 18, 2011 Using chemical compounds found in a Japanese ... light, a Scripps Research Institute team has created a unique ... potential. Already, one of the compounds has shown great promise ... With the report of their work scheduled to appear ...
Cached Biology News:Genetic origin of cultivated citrus determined 2Unlocking the secret(ase) of building neural circuits 2Unlocking the secret(ase) of building neural circuits 3Scripps Research team creates new synthetic compound with HIV-fighting promise 2Scripps Research team creates new synthetic compound with HIV-fighting promise 3
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... 2014 ITRA Global, one of the ... commercial real estate, has further expanded its global reach ... and Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman ... ITRA Global / ACORPP (Australian Corporate Property and Projects) ... providing property services to a wide range of clients ...
(Date:12/19/2014)... Naurex Inc., a biopharmaceutical company leveraging its ... the central nervous system, today announced that Norbert ... present at the 33 rd annual J.P. Morgan ... 3:00 p.m. PST on Tuesday, January 13, 2015, at ... Calif. About Naurex Inc. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... a,specialist in antibiotics development, announces that Dr. George ... the Company., Dr. Golumbeski brings to the ... recently as Vice President of Business Development,Licensing & ... In this,position he was responsible for the full ...
... July 2 /Xinhua-PRNewswire-FirstCall/,-- China Pharma Holdings, Inc. (,China ... markets generic and branded bio-,pharmaceutical products in China, ... Collins Stewart Fourth Annual Growth Conference on Tuesday,July ... being held at the Mandarin,Oriental Hotel in New ...
... new therapies based on cells manufactured from ... provide funding round, SALT LAKE CITY and HAMBURG, ... the forefront of innovative cell therapies,for the treatment of ... Series A financing. The round was led by SV ...
Cached Biology Technology:Nabriva Therapeutics Announces Appointment of New CEO 2China Pharma Holdings, Inc. to Present at Collins Stewart Fourth Annual Growth Conference in New York on July 8, 2008 at 2:00 p.m. EDT 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 3
... cooling coil, Trans-Blot cell, provides ... high-intensity, and extended electrophoretic transfer ... Trans-Blot cell. Use of the ... to an external water recirculator, ...
... of next-generation features into a small-footprint design, ... flexible laboratory solutions. It puts every aspect ... dispensing, and integrations into a single, ... as it is efficient and economical. The ...
... Biomek FX P is the latest entry ... for greater positional accuracy and increased robustness, it ... application. It can be configured with either one ... capacity, the Biomek FX P sets the ...
These Costar 96-well, flat-bottom polystyrene EIA plates are used for EIAs, ELISAs, and other protein binding assays. Supplied as box of 100 (20 packages; 5 plates per package)....
Biology Products: